| 孙元珏.晚期软组织肉瘤新药临床应用进展[J].肿瘤学杂志,2017,23(11):959-966. |
| 晚期软组织肉瘤新药临床应用进展 |
| Clinical Application Progress on New Drugs in Advanced Soft-tissue Sarcoma |
| 投稿时间：2017-01-22 |
| DOI：10.11735/j.issn.1671-170X.2017.11.B005 |
|
 |
| 中文关键词: 肿瘤，结缔和软组织 药物疗法 抗肿瘤药 |
| 英文关键词:neoplasms connective and soft tissue drug therapy antineoplastic agents |
| 基金项目: |
|
| 摘要点击次数: 2335 |
| 全文下载次数: 2008 |
| 中文摘要: |
| 摘 要：软组织肉瘤是一组来源于间叶组织的恶性肿瘤，病理类型繁多。对于不可切除的局部晚期或转移性软组织肉瘤，以姑息性化疗为主的多学科综合治疗有利于减轻患者症状、延长总生存期和提高生活质量。蒽环类药物和异环磷酰胺仍是软组织肉瘤化疗的基石，近年来曲贝替定、艾瑞布林等新型化疗药物和培唑帕尼、Olaratumab等分子靶向药物相继问世，获批用于晚期软组织肉瘤的内科治疗，免疫检查点抑制剂PD-1/PD-L1单抗的异军突起，更是给晚期软组织肉瘤的免疫治疗带来了新的曙光。 |
| 英文摘要: |
| Abstract：Soft-tissue sarcomas(STS) are a group of malignant tumors derived from mesenchymal tissue with various pathological types. For unresectable locally advanced and metastatic soft-tissue sarcomas，palliative chemotherapy as an important role of multi-disciplinary comprehensive treatment is able to relieve symptoms，prolong the overall survival and improve the quality of life predominantly.Anthracycline-based drugs and ifosfamide still serve as the foundation of chemotherapy for soft-tissue sarcomas. In recent years，trabectedin，eribulin，pazopanib，olaratumab and other new types of anti-tumors drugs were approved for medical treatment in advanced soft-tissue sarcoma. The appearance of immune checkpoint inhibitors such as PD-1/PD-L1 monoclonal antibodies has also provided new prospect for immunotherapy of advanced soft-tissue sarcomas. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |